Anti-tryptase antibodies, compositions thereof, and uses thereof
The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
1. An isolated nucleic acid, or a set of isolated nucleic acids, encoding an antibody that binds to human tryptase beta 1, or an antigen-binding fragment thereof, wherein the antibody comprises the following six hypervariable regions (HVRs):
(a) an HVR-H1 comprising the amino acid sequence of DYGMV (SEQ ID NO: 7);
(b) an HVR-H2 comprising the amino acid sequence of FISSGSSTVYYADTMKG (SEQ ID NO: 2);
(c) an HVR-H3 comprising the amino acid sequence of RNYDDWYFDV (SEQ ID NO: 8);
(d) an HVR-L1 comprising the amino acid sequence of SASSSVTYMY (SEQ ID NO: 4);
(e) an HVR-L2 comprising the amino acid sequence of RTSDLAS (SEQ ID NO: 5); and
(f) an HVR-L3 comprising the amino acid sequence of QHYHSYPLT (SEQ ID NO: 6).
2. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody comprises (a) a VH domain comprising an amino sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 9; (b) a VL domain comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 10; or (c) a VH domain as in (a) and a VL domain as in (b).
3. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 2 , wherein the antibody comprises (a) a VH domain comprising an amino sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10; or (c) a VH domain as in (a) and a VL domain as in (b).
4. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 3 , wherein the antibody comprises (a) a VH domain comprising an amino sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 9; (b) a VL domain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 10; or (c) a VH domain as in (a) and a VL domain as in (b).
5. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9.
6. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 10.
7. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody is capable of dissociating both the small interface of tetrameric human tryptase beta 1 and the large interface of tetrameric human tryptase beta 1.
8. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody further binds cynomolgus monkey tryptase, human tryptase alpha, human tryptase beta 2 and/or human tryptase beta 3.
9. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody binds the tryptase with a KD of about 1 nM or less.
10. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 9 , wherein the antibody binds the tryptase with a KD of between about 120 pM and about 0.5 nM.
11. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 10 , wherein the antibody binds tryptase with a KD of about 400 pM.
12. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody is capable of inhibiting the enzymatic activity of human tryptase beta 1.
13. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 12 , wherein the antibody inhibits the activity of tryptase with an IC50 of about 2.5 nM or lower as determined by a human tryptase beta enzymatic assay using a colorimetric synthetic peptide substrate.
14. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein:
(i) the antibody is capable of inhibiting the enzymatic activity of human tryptase beta 1 at pH 6;
(ii) the antibody is capable of inhibiting tryptase-mediated stimulation of bronchial smooth muscle cell proliferation and/or collagen-based contraction;
(iii) the antibody is capable of inhibiting mast cell histamine release;
(iv) the antibody is capable of inhibiting IgE-triggered histamine release and/or tryptase-triggered histamine release;
(v) the antibody is capable of inhibiting tryptase activity in cynomolgus monkey broncheoloar lavage (BAL) or nasosorption samples;
(vi) the antibody is capable of dissociating tetrameric human tryptase beta 1;
(vii) the antibody is capable of dissociating tetrameric human tryptase beta 1 when in a monovalent format; and/or
(viii) the antibody is capable of dissociating tetrameric human tryptase beta 1 in the presence of heparin.
15. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody is monoclonal or humanized.
16. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody is an IgG antibody.
17. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 16 , wherein the IgG antibody is an IgG1 antibody or an IgG4 antibody.
18. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 17 , wherein the IgG4 antibody comprises an S228P mutation in the heavy chain constant region according to the EU numbering system.
19. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 1 , wherein the antibody is a monospecific antibody or a multispecific antibody.
20. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 19 , wherein the multispecific antibody is a bispecific antibody.
21. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 20 , wherein the antibody comprises a first binding domain that binds to human tryptase beta 1 and a second binding domain that binds to a second biological molecule, wherein the second biological molecule is selected from the group consisting of interleukin-13 (IL-13), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-17 (IL-17), IgE, and interleukin-33 (IL-33).
22. An isolated nucleic acid, or a set of isolated nucleic acids, encoding an antibody that binds to human tryptase beta 1, or an antigen-binding fragment thereof, comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 10, wherein the nucleic acid or the set of nucleic acids comprises a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 104 and/or SEQ ID NO: 105.
23. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 22 , comprising a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 104 and/or SEQ ID NO: 105.
24. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 23 , comprising a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 104 and/or SEQ ID NO: 105.
25. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 24 , comprising a sequence having at least 99% sequence identity to the sequence of SEQ ID NO: 104 and/or SEQ ID NO: 105.
26. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 25 , comprising the sequence of SEQ ID NO: 104 and/or SEQ ID NO: 105.
27. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 22 , wherein the antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 76 and/or (b) a light chain comprising the amino acid sequence of SEQ ID NO: 77, and wherein the nucleic acid or the set of nucleic acids comprises a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 106 and/or SEQ ID NO: 107.
28. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 27 , comprising a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 106 and/or SEQ ID NO: 107.
29. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 28 , comprising a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 106 and/or SEQ ID NO: 107.
30. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 29 , comprising a sequence having at least 99% sequence identity to the sequence of SEQ ID NO: 106 and/or SEQ ID NO: 107.
31. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 30 , comprising the sequence of SEQ ID NO: 106 and/or SEQ ID NO: 107.
32. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 22 , wherein the antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 78 and/or (b) a light chain comprising the amino acid sequence of SEQ ID NO: 77, and wherein the nucleic acid or the set of nucleic acids comprises a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 108 and/or SEQ ID NO: 107.
33. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 32 , comprising a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 108 and/or SEQ ID NO: 107.
34. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 33 , comprising a sequence having at least 95% identical to the sequence of SEQ ID NO: 108 and/or SEQ ID NO: 107.
35. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 34 , comprising a sequence having at least 99% sequence identity to the sequence of SEQ ID NO: 108 and/or SEQ ID NO: 107.
36. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 35 , comprising the sequence of SEQ ID NO: 108 and/or SEQ ID NO: 107.
37. An isolated nucleic acid, or a set of isolated nucleic acids, encoding an antibody that binds to human tryptase beta 1, or an antigen-binding fragment thereof, wherein the antibody comprises (a) a VH domain comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 9 and (b) a VL domain comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 10.
38. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 37 , wherein the antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10.
39. An isolated nucleic acid, or a set of isolated nucleic acids, encoding an antibody comprising (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 76 or SEQ ID NO: 78 and (b) a light chain comprising the amino acid sequence of SEQ ID NO: 77.
40. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 39 , wherein the antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 76 and (b) a light chain comprising the amino acid sequence of SEQ ID NO: 77.
41. The isolated nucleic acid, or the set of isolated nucleic acids, of claim 39 , wherein the antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 78 and (b) a light chain comprising the amino acid sequence of SEQ ID NO: 77.
42. A vector or a set of vectors comprising the isolated nucleic acid or set of isolated nucleic acids of claim 1 .
43. An isolated host cell comprising the vector or set of vectors of claim 42 .
44. The isolated host cell of claim 43 , wherein the host cell is a mammalian cell or a prokaryotic cell.
45. A method of producing an antibody that binds to human tryptase beta 1, the method comprising culturing the isolated host cell of claim 43 in a culture medium under suitable conditions that allow production of the antibody.